Boulder-based Clovis sees stock surge as FDA approves accelerated review of ovarian cancer drug

Boulder Daily Camera – Shares of Boulder-based Clovis Oncology (NASDAQ: CLVS) were up on news that the Food and Drug Administration accepted the drug maker’s application for an accelerated review of its advanced ovarian cancer drug, rucaparib. Learn more.

Scroll to Top